Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1,821 articles
Plant-derived exosome-like nanovesicles (PENs) carry lipids, proteins, and RNA with potent anti-aging and skin-repair properties.
The neutrophil-to-lymphocyte ratio rises with age and predicts disease risk — and centenarians show a slower increase, hinting at immune resilience.
Rockefeller scientists mapped epigenomic aging across 7M cells in 21 tissues, uncovering coordinated, program-like shifts that may unlock new therapies.
SimonMed is expanding AI imaging tools that extract cardiovascular, bone, and spine risk data from scans patients already get.
Twenty global teams win funding and data access to find new ALS drug targets using AI and multi-omics — a potential model for all aging diseases.
Pegsebrenatide, a long-acting GLP-1 receptor agonist, is now in human trials targeting neurodegeneration in progressive MS — with broad longevity implications.
Epigenetic clock pioneer Steve Horvath explains why the field is converging on validated biomarkers to make longevity medicine actionable.
From a massive family study of centenarians to a paradigm shift in how aging is measured, longevity science is evolving fast.
A longitudinal mouse study identifies sex-specific plasma metabolite biomarkers of frailty, pointing to B vitamins in females and lipids in males.
A 2025 review maps how quercetin fights senescence, oxidative stress, and inflammation in AMD, cataract, diabetic retinopathy, and glaucoma.
A randomized trial finds quercetin reduces vascular senescence and inflammation in male CAD patients undergoing bypass surgery, with no benefit in females.
Contrary to expectations, breeding boobies elongated their telomeres during incubation — suggesting individual quality drives telomere dynamics.
